| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Andrew C. Von Eschenbach is Director at CELU, with reported holdings spanning 3 companies. Andrew C. Von Eschenbach's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.9M at current prices.
Our model assigns Andrew C. Von Eschenbach a below-average insider score of 46/100, based on 3 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -18.3%.
Andrew C. Von Eschenbach's largest disclosed position is in BLCO as Director, worth about $1.3M. The BLCO filings lean toward selling, a net 12,500 shares.
Andrew C. Von Eschenbach has 22 Form 4 filings on record from October 2018 to August 2026, across 4 companies: Director at Bausch + Lomb (BLCO), 2022–2026; Director at TriSalus Life Sciences (TLSI), 2023–2024; Director at Celularity (CELU), 2021–2023, and 1 more.
The 28 reported transactions were 12 stock awards, 7 option or other derivative awards, 4 open-market purchases and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 4 purchases worth about $156K and 1 sale worth about $307K.
The largest open-market purchase was 4,364 shares of BLCO at an average $18.30 on February 27, 2026, about $80K.
The only open-market sale was 18,559 shares of BLCO at an average $16.53 on August 7, 2026, about $307K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | BLCO Bausch + Lomb Corporation | Director | Sell | 18,559 | $16.53 | $306,708.22 | -22.6% | - | - | |
| Feb 27, 2026 | BLCO Bausch + Lomb Corporation | Director | Buy | 4,364 | $18.31 | $79,883.02 | +7.0% | -14.8% | - | |
| May 2, 2025 | BLCO Bausch & Lomb Corp | Director | Buy | 1,695 | $11.76 | $19,924.73 | +4.2% | +18.5% | +41.8% | |
| Aug 5, 2021 | BHC Bausch Health Companies Inc. | Director | Buy | 1,400 | $25.94 | $36,316.00 | +3.8% | +5.1% | -78.4% | |
| Mar 10, 2020 | BHC Bausch Health Companies Inc. | Director | Buy | 1,100 | $18.18 | $19,996.35 | +6.3% | - | - |